This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fonseca, V. A Search for Related Content Social Bookmarking                         What's this?

Defining and characterising the progression of type 2 diabetes

Section of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana, USA, vfonseca{at}tulane.edu

Type 2 diabetes is a progressive disease characterised by worsening of multiple abnormalities and loss of glycaemic control over time. An increasing need for glucose-lowering treatments is emphasised by the almost inevitable failure of monotherapy and occurrence of weight gain. Longer survival times and development of type 2 diabetes at a younger age also increase the risk of developing microvascular and macrovascular complications. A hallmark of type 2 diabetes mellitus is declining pancreatic β -cell function, which begins years before diagnosis and continues throughout the disease process. This deterioration continues despite initiation of numerous therapies, as these interventions lower glucose but do not directly slow β -cell decline and dysfunction. Defects in -cell function are also important contributors to disease progression. New therapies that can counter these abnormalities without causing weight gain or hypoglycaemia continue to be assessed. Br J Diabetes Vasc Dis, 2008; 8 (suppl 2): S3—S9

Key Words: β cell • glycaemic control • impaired glucose tolerance • pathogenesis • type 2 diabetes.

References

• Stratton IM, Adler AI, Neil AW et al. On behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.[Abstract/Free Full Text]
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kahn SE, Haffner SM, Heise MA et al. For the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.[Abstract/Free Full Text]
• Holman RR Assessing the potential for a-glucosidase inhibitors in pre-diabetic states. Diabetes Res Clin Pract 1998;40(suppl):S21-5.[Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.[Abstract]
• Riddle MC, Rosenstock J., Gerich J. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.[Abstract/Free Full Text]
• Nathan DM Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-9.[Free Full Text]
• Buchanan TA Pancreatic beta-cell loss and preservation in type 2 diabetes. Clin Ther 2003;25(suppl B):B32-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kahn SE The importance of β-cell failure in the development and progression of type 2 diabetes [clinical review 135]. J Clin Endocrinol Metab 2001;86:4047-58.[Free Full Text]
• DeFronzo RA Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhou Y.-P, Grill V. Long term exposure to fatty acids and ketones inhibits β-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995;80:1584-90.[Abstract/Free Full Text]
• Zhou Y.-P, Grill V. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 1994;93:870-6.[Web of Science][Medline] [Order article via Infotrieve]
• Sako Y., Grill VE A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and β cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990;127:1580-9.[Abstract/Free Full Text]
• Hayashi T., Boyko EJ, McNeely MJ et al. Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes 2008; 57:1269-75.[CrossRef][Medline] [Order article via Infotrieve]
• Gastaldelli A., Cusi K., Pettiti M. et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cnop M., Vidal J., Hull RL et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007;30:677-82.[Abstract/Free Full Text]
• Frayling TM, Evans JC, Bulman MP et al. β-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 2001;50(suppl 1):S94-100.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stride A., Hattersley AT Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med 2002;34:207-16.[Web of Science][Medline] [Order article via Infotrieve]
• Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978;108:497-505.[Abstract/Free Full Text]
• Weyer C., Bogardus C., Mott DM, Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.[Web of Science][Medline] [Order article via Infotrieve]
• Festa A., Williams K., D'Agostino R. Jr et al. The natural course of β-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006;55:1114-20.[Abstract/Free Full Text]
• Porte D. Jr, Kahn SE β-Cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001;50(suppl 1):S160-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442-8.[Web of Science][Medline] [Order article via Infotrieve]
• Prentki M., Joly E., El-Assaad W., Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in β-cell adaptation and failure in the etiology of diabetes. Diabetes 2002;51(suppl 3):S405-13.[Abstract/Free Full Text]
• Wallace TM, Matthews DR Coefficient of failure: a methodology for examining longitudinal β-cell function in type 2 diabetes. Diabetes Med 2002;19:465-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pick A., Clark J., Kubstrup C. et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998;47:358-64.[Abstract]
• Butler AE, Janson J., Bonner-Weir S. et al. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.[Abstract/Free Full Text]
• Ritzel RA, Butler AE, Rizza RA et al. Relationship between β-cell mass and fasting blood glucose concentration in humans. Diabetes Care 2006;29:717-8.[Free Full Text]
• Deng S., Vatamaniuk M., Huamg X. et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004;53:624-32.[Abstract/Free Full Text]
• Fonseca V., Berger LA, Beckett AG, Dandona P. Size of pancreas in diabetes mellitus: a study based on ultrasound. BMJ 1985;291: 1240-1.[Free Full Text]
• Goda K., Sasaki E., Nagata K. et al. Pancreatic volume in type 1 and type 2 diabetes mellitus. Acta Diabetologia 2001;38:145-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005;48:1700-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 2 Suppl, S3-S9 (2008)
DOI: 10.1177/1474651408100520


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fonseca, V. A Search for Related Content Social Bookmarking                         What's this?